Charles Delisi, a professor of science and engineering and the dean emeritus of Boston University College of Engineering, has been appointed to Strand Genomics’ scientific advisory board. The Bangalore, India-based bioinformatics company chose Delisi due to his “unique insights” into the high-throughput genomics sector. Delisi heads the biomolecular systems laboratory at the Center for Advanced Genomic Technology in Boston.
Nina Giles has been appointed the new vice president of business development at Hyseq Pharmaceuticals, the Sunnyvale, Calif., parent of sequencing microarray maker Callida Genomics. Giles previously worked in various management positions at Incyte from 1997 to 2002, most recently serving as vice president, business development. Giles has also held both analyst and management positions at Frost & Sullivan. She holds a bachelors degree from the University of California Davis.
Leroy Hood, founder of the Institute for Systems Biology in Seattle and a board member of Lynx Therapeutics, has been named as the recipient of the 2002 Kyoto Prize in area of Advanced Technology, The Inamori Foundation of Japan, which administers the award, will present Hood and the other laureates with diplomas, a Kyoto Prize gold medal, and a cash gift of 50 million yen ($400,000), during a prize ceremony in Kyoto on November 10. The laureates will also convene in San Diego, between March 5 and 7, 2003, for the second annual Kyoto Laureate Symposium at the University of San Diego. Hood was cited for his invention of automated sequencing machines, which facilitated the mapping of the human genome.
Lynx Therapeutics has appointed Thomas Vasicek as vice president of business development. Vasicek most recently served as chief scientific officer at LabSeek Scientific Collaborative. Previously, he was director of commercial technology at the Corning Advanced Life Sciences products division, where he managed the effort to establish Corning’s commercial DNA microarray capabilities. Vasicek also worked at Millennium Pharmaceuticals, developing and managing several of Millennium’s agreements with pharma and agribusiness. Vasicek has a PhD in chemistry and molecular biology from Harvard Medical School and a BS from the Massachusetts Institute of Technology. This appointment comes just after the company replaced CEO Norrie Russell with vice president Kevin Corcoran, and announced that chief scientific officer Richard Woychik would leave in August to head the Jackson Lab in Maine.